ibandronic acid

This medicine is authorised for use in the European Union.


This is a summary of the European public assessment report (EPAR) for Bondronat. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Bondronat.

This EPAR was last updated on 14/07/2023

Authorisation details

Product details
Agency product number
Active substance
ibandronic acid
International non-proprietary name (INN) or common name
ibandronic acid
Therapeutic area (MeSH)
  • Hypercalcemia
  • Breast Neoplasms
  • Neoplasm Metastasis
  • Fractures, Bone
Anatomical therapeutic chemical (ATC) code
Publication details
Marketing-authorisation holder
Atnahs Pharma Netherlands B.V.
Date of issue of marketing authorisation valid throughout the European Union
Contact address

Copenhagen Towers,
Ørestads Boulevard 108,
DK-2300 København S

Product information

19/05/2023 Bondronat - EMEA/H/C/000101 - IB/0091/G

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.


Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Drugs for treatment of bone diseases

Therapeutic indication

Bondronat is indicated for:

  • prevention of skeletal events (pathological fractures, bone complications requiring radiotherapy or surgery) in patients with breast cancer and bone metastases;
  • treatment of tumour-induced hypercalcaemia with or without metastases.

Assessment history

How useful was this page?

Add your rating